Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer
28 sept. 2023 16h11 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics...
Molecular Templates Announces 1-for-15 Reverse Stock Split
11 août 2023 11h22 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) (the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with...
Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update
10 août 2023 08h08 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Announces Executive Leadership Changes
02 août 2023 16h11 HE
|
Molecular Templates, Inc.
Dr. Gabriela Gruia to assume the role of interim Chief Medical OfficerJason Kim to assume the role of President and Chief Financial OfficerKristen Quigley to assume the role of Chief Operating...
Molecular Templates Announces Up to $40 Million Private Placement Offering
13 juil. 2023 08h14 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Announces Debt Payoff and Restructuring
16 juin 2023 20h56 HE
|
Molecular Templates, Inc.
Restructuring agreement with K2 HealthVentures (K2HV) to fully discharge and satisfy outstanding debt owed to K2HV for the prepayment of $27.5 million and the granting of contingent value rights and...
Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma
01 juin 2023 07h57 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
26 mai 2023 17h10 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, May 26, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update
15 mai 2023 16h13 HE
|
Molecular Templates, Inc.
Advancing clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to Bristol Myers Squibb collaboration AUSTIN, Texas, May 15, 2023 (GLOBE NEWSWIRE) -- Molecular...
Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169
07 avr. 2023 18h50 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, April 07, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), today announced that the U.S. Food and Drug Administration (the “FDA”)...